Why Health Systems Are Bringing Denial Management In-House (And What It Actually Takes)

Something has shifted in how health systems think about denial management over the last two years. Organizations that once relied heavily on third-party vendors are increasingly reconsidering that arrangement, not because the vendors necessarily failed, but because the underlying economics and the available technology have changed enough to make internal operations worth evaluating.

This isn't a universal trend, and it's not the right move for every organization. But understanding what's driving it, and what the operational requirements actually look like, is relevant for any revenue cycle leader weighing the options.

What's Pushing Systems Toward In-House Denials Management?

The cost argument has become more concrete. When denial volumes are moderate and payer behaviors are relatively predictable, a success-fee arrangement with a vendor can make sense. The vendor assumes some risk, your team isn't burdened, and the math works. But as denial rates climb and volumes grow, that calculus changes.

Denial rates vary substantially by insurance type and clinical setting: with published data showing rates of 20% for ACA marketplace plans and 17% for Medicare Advantage claims (JAMA Health Forum, 2025). What's consistent across settings is the direction of travel: 77% of providers report denial volumes increasing, a jump from 42% just two years prior (Health Affairs, 2025).

At higher volumes, the 10% success fee common in the industry starts to represent a significant annual expense. Organizations doing the math are sometimes finding that building internal capability, with the right technology infrastructure, produces better economics at their scale, with the added benefit of institutional knowledge that doesn't walk out the door with a vendor relationship.

There's also a quality control dimension. Denial appeal letters generated by vendors aren't always built to the hospital's specific clinical context, payer relationships, or documentation standards. Revenue cycle leaders at academic medical centers and large health systems in particular have expressed frustration with generic letter templates that don't reflect the complexity of their cases.

What Most Organizations Underestimate

The power of internal control is appealing but the operational requirements are also significant, and organizations that underestimate them tend to struggle in the transition.

Denial management at scale requires more than trained staff with access to medical records. It requires a system that can ingest denial data from clearinghouses and payers, prioritize which denials are worth pursuing, automatically retrieve relevant clinical documentation, and support staff in constructing high-quality appeals across multiple payer types with different criteria and submission requirements.

Without that infrastructure, you're essentially asking experienced revenue cycle professionals to do manual, time-intensive work that vendors were handling for you. The result is often a staffing problem disguised as a strategy.

The administrative burden is substantial. One analysis estimated the healthcare sector deals with $11 to $54 billion in challenged revenue annually (JAAOS, 2020), and the labor component of that figure is significant. Constructing a thorough appeal for a complex clinical denial can require hours of skilled staff time per case, and at high volumes, that's a resource constraint that limits how many eligible denials you can realistically pursue.

The Technology Prerequisite

Organizations that have successfully transitioned to internal denial management share one common thread: they invested in the right technology infrastructure before or alongside the transition, not after.

What that infrastructure needs to support includes denial data ingestion from your existing clearinghouse or EMR, intelligent prioritization based on dollar value, appeal deadline, and likelihood of overturn, automated clinical documentation retrieval through FHIR or direct EMR integration, and appeal letter generation that internal staff can review and submit at a fraction of the time manual drafting requires.

The human expertise in your revenue cycle team remains essential. What technology does is eliminate the manual, time-consuming work that limits how many cases that expertise can be applied to. A well-built denial management platform doesn't replace your team; it determines whether your team's capacity is spent on clinical judgment or on administrative assembly.

Cofactor AI's approach specifically reduces the time to produce a complete, documentation-backed appeal from an average of 1 to 4 hours down to approximately 10 to 15 minutes per case, which is what makes internal operations viable at scale without proportional headcount growth.

The Hidden Revenue Opportunity

One of the most compelling arguments for bringing denial management in-house with the right technology isn't cost reduction. It's the ability to appeal a far higher percentage of eligible denials than traditional models allow.

The appeal success rates tell a clear story. Across Medicare Advantage, medical necessity disputes, and independent medical reviews, roughly half of all appealed denials are ultimately overturned (Health Affairs, 2025; JAMA Health Forum, 2025).

Yet fewer than 1% of marketplace plan denials and only 11.7% of Medicare Advantage prior authorization denials are ever appealed (JAMA Health Forum, 2025). That gap is largely economic. When appeal generation requires hours of skilled staff time, selective pursuit is the only rational strategy. Many legitimate denials go uncontested simply because the cost of contesting them exceeds the expected recovery.

When that time drops to 10 to 15 minutes per case, the economics change entirely. Denials that weren't worth appealing under traditional models become worth pursuing. Organizations that have made this shift are seeing ROI not from doing existing work faster, but from recovering revenue that was never being pursued at all.

Making the Decision

The in-house versus vendor question doesn't have a universal answer. What matters is evaluating it with accurate information about your denial volumes, your current recovery rates, your vendor costs, and the infrastructure investment required to make internal operations viable.

The feasibility calculation has shifted. Building internal denial management capability no longer requires building an enormous team. It requires building the right infrastructure, and deciding who you want applying clinical judgment to the cases your system surfaces. For organizations at sufficient scale, the economics are increasingly compelling, and the revenue opportunity goes well beyond what traditional models were able to capture.

---

If you're weighing whether internal denial management makes sense for your organization, the answer starts with your own data.

Calculate My ROI